Results 21 to 30 of about 2,198 (193)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report [PDF]

JTO Clinical and Research Reports, 2022
Introduction: RET is well known as an important driver gene in NSCLC. Moreover, RET is a rare acquired resistance mechanism to EGFR-mutant NSCLC. Only 36 NSCLC cases of coexistence of EGFR and RET were reported previously worldwide.
Zichen Zhao, MD, Chao Su, PhD, Weigang Xiu, MD, Weiya Wang, MD, Shasha Zeng, MD, Meijuan Huang, MD, Youling Gong, MD, You Lu, MD, PhD, Yan Zhang, MD, PhD   +8 more
doaj   +2 more sources

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement [PDF]

Frontiers in Oncology, 2022
RET rearrangements are rare, and occur in 1%-2% of all non-small cell lung cancer (NSCLC) patients. Pralsetinib has a significant anti-tumor effect in patients with advanced NSCLC and a RET rearrangement. Previous studies have confirmed the efficiency of
Ning Zhou, Ning Zhou, Tong Li, Tong Li, Maoli Liang, Fan Ren, Fan Ren, Hong Ni, Hong Ni, Wei Liu, Tao Shi, Dongbo Xu, Qiusong Chen, Haonan Yu, Zuoqing Song, Zuoqing Song, Lingling Zu, Lingling Zu, Shuo Li, Song Xu, Song Xu   +20 more
doaj   +2 more sources

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer [PDF]

Supportive Care in Cancer, 2023
Abstract Objective Oncogenic alternation in RET is one of the important targets of non-small cell lung cancer (NSCLC). Pralsetinib has shown great efficacy in RET fusion-positive NSCLC, but a series of adverse reactions will inevitably occur in the meantime.
Gao, Ming, Zhang, Xia, Yan, Huan, Sun, Decong, Yang, Xuejiao, Yuan, Fang, Ju, Yanfang, Wang, Lijie, Wang, Jinliang, Zhao, Wei, Zhang, Dong, Li, Lin, Xu, Xiaoyun, Ma, Junxun, Hu, Yi, Zhang, Xiaotao   +15 more
openaire   +3 more sources

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial [PDF]

, 2022
RET inhibition; Pralsetinib; Targeted therapyInhibición de RET; Pralsetinib; Terapia dirigidaInhibició de RET; Pralsetinib; Teràpia dirigidaBackground RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC).
Frank Griesinger, Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan, Daniel Lee, D Misch, Elena Garralda, D.-W. Kim, Anthonie J. van der Wekken, Justin F. Gainor, Luis Paz‐Ares, Stephen V. Liu, Gregory P. Kalemkerian, Yariv Houvras, Daniel W. Bowles, Aaron S. Mansfield, W. Marston Linehan, Vlatka Smoljanović, Ahmadur Rahman, Shengchun Kong, Alena Zalutskaya, Melinda Louie-Gao, Andy Boral, Julien Mazières   +25 more
openalex   +4 more sources

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC [PDF]

JTO Clinical and Research Reports
Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, RET fusion-positive NSCLC. Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET fusion-positive NSCLC ...
Francesca Lucibello, MD, Valérie Gounant, MD, PhD, Mihaela Aldea, MD, PhD, Michaël Duruisseaux, MD, PhD, Maurice Perol, MD, Christos Chouaid, MD, Jaafar Bennouna, MD, PhD, Vincent Fallet, MD, Aldo Renault, MD, Florian Guisier, MD, PhD, Etienne Giroux-Leprieur, MD, PhD, Marie Wislez, MD, PhD, Anne-Claire Toffart, MD, PhD, Julien Mazieres, MD, PhD, Clémence Basse, MD, PhD, Nadia Hegarat, PhD, Matthieu Carton, MD, Nicolas Girard, MD, PhD   +17 more
doaj   +2 more sources

Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer [PDF]

Frontiers in Oncology
The global incidence of thyroid cancer has increased significantly, and patients with advanced, recurrent, or radioiodine-refractory disease face a severe shortage of effective treatment options.
Yulu Zhou, Yulu Zhou, Junjie Cao, Siqi Zhang, Mingjun Sun, Yaqi Zhang, Songzhe Li, Zining Luo, Pengyu Wang, Jiebin Xie   +9 more
doaj   +2 more sources

Sequential targeted therapy in synchronous dual-primary lung adenocarcinomas with EGFR and RET alterations: a 5-year follow-up case report [PDF]

Frontiers in Oncology
With the increasing detection of multiple primary pulmonary nodules, accurately distinguishing between multiple primary lung cancers and intrapulmonary metastasis is crucial for diagnosis and treatment.
Yong-liang Niu, Ying Yang, Xiao-bao Teng, Ming-feng Han, Di-ming Wang   +4 more
doaj   +2 more sources

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report

Cancer Management and Research, 2023
Hao Qin,1,* Yuxiang Wan,2,* Yuchao Dong,1 Qinying Sun1 1Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, People’s Republic of China ...
Qin H, Wan Y, Dong Y, Sun Q
doaj   +3 more sources

Development and validation of a novel high-performance liquid chromatography (HPLC) method for the detection of related substances of pralsetinib, a new anti-lung cancer drug [PDF]

Frontiers in Chemistry
BackgroundPralsetinib, a targeted inhibitor of the RET enzyme, plays a critical role in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by RET gene fusion mutations following platinum ...
Yonghong Zhu, Jisu Qin, Wenyi Wu, Liangliang Cai   +3 more
doaj   +2 more sources

Pralsetinib (Gavreto)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
CADTH
openaire   +3 more sources